Pulmatrix (PULM) Competitors $6.66 -0.11 (-1.61%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. ALTS, MGNX, EXOZ, GALT, ANIX, TCRX, KYTX, VOR, BDTX, and ENTXShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Janone (ALTS), MacroGenics (MGNX), Exozymes (EXOZ), Galectin Therapeutics (GALT), Anixa Biosciences (ANIX), TScan Therapeutics (TCRX), Kyverna Therapeutics (KYTX), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Janone MacroGenics Exozymes Galectin Therapeutics Anixa Biosciences TScan Therapeutics Kyverna Therapeutics Vor Biopharma Black Diamond Therapeutics Entera Bio Janone (NASDAQ:ALTS) and Pulmatrix (NASDAQ:PULM) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Does the media prefer ALTS or PULM? In the previous week, Janone and Janone both had 2 articles in the media. Pulmatrix's average media sentiment score of 1.89 beat Janone's score of 1.28 indicating that Pulmatrix is being referred to more favorably in the news media. Company Overall Sentiment Janone Positive Pulmatrix Very Positive Which has more risk & volatility, ALTS or PULM? Janone has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Which has stronger valuation & earnings, ALTS or PULM? Janone has higher revenue and earnings than Pulmatrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$12.53M8.11-$7.81MN/AN/APulmatrix$7.81M3.14-$14.12M-$2.61-2.57 Is ALTS or PULM more profitable? Janone has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pulmatrix's return on equity of -45.97% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Pulmatrix -96.51%-45.97%-30.72% Do institutionals & insiders hold more shares of ALTS or PULM? 6.3% of Janone shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 4.9% of Janone shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in ALTS or PULM? Pulmatrix received 196 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/APulmatrixOutperform Votes19648.28% Underperform Votes21051.72% SummaryJanone beats Pulmatrix on 6 of the 11 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.49M$6.71B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.28%P/E Ratio-2.547.2322.3918.44Price / Sales3.14239.71391.41101.46Price / CashN/A65.8538.1834.62Price / Book1.366.306.684.19Net Income-$14.12M$143.17M$3.22B$248.05M7 Day Performance6.19%8.00%6.24%6.54%1 Month Performance-0.30%-4.16%-2.81%-2.16%1 Year Performance228.92%-2.78%16.47%4.71% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.8326 of 5 stars$6.71-0.9%N/A+222.6%$24.49M$7.81M-2.5420Short Interest ↓Positive NewsALTSJanoneN/A$5.56+8.0%N/AN/A$89.40M$12.53M0.00170Positive NewsGap DownMGNXMacroGenics3.8723 of 5 stars$1.39+10.3%$7.38+430.6%-88.1%$87.70M$148.34M-0.88430News CoveragePositive NewsEXOZExozymesN/A$10.47-3.4%N/AN/A$87.61MN/A0.0029Gap UpGALTGalectin Therapeutics1.0639 of 5 stars$1.31-5.1%$11.00+739.7%-62.3%$87.19MN/A-1.799ANIXAnixa Biosciences2.4726 of 5 stars$2.69-1.1%$9.00+234.6%-7.4%$86.61M$210,000.00-6.905TCRXTScan Therapeutics3.6812 of 5 stars$1.53+6.3%$9.33+510.0%-78.1%$86.58M$2.82M-1.44100KYTXKyverna Therapeutics2.0573 of 5 stars$1.99+7.0%$18.33+821.3%-86.8%$86.01M$7.03M-0.5796VORVor Biopharma2.2445 of 5 stars$0.69+5.6%$8.86+1,190.4%-57.7%$85.70MN/A-0.42140Gap UpBDTXBlack Diamond Therapeutics3.4522 of 5 stars$1.49+3.5%$14.60+879.9%-68.9%$84.43MN/A-1.1290Positive NewsGap DownENTXEntera Bio2.0972 of 5 stars$1.84+2.8%$10.00+443.5%+20.0%$83.58M$181,000.00-7.0820News Coverage Related Companies and Tools Related Companies Janone Alternatives MacroGenics Alternatives Exozymes Alternatives Galectin Therapeutics Alternatives Anixa Biosciences Alternatives TScan Therapeutics Alternatives Kyverna Therapeutics Alternatives Vor Biopharma Alternatives Black Diamond Therapeutics Alternatives Entera Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PULM Stock Free PULM Stock Alerts